Date: 2017-05-02
Type of information: Nomination
Compound:
Company: Curevac (Germany)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 2, 2017, CureVac announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston based U.S. subsidiary. Mr. Menichella will develop CureVac’s US organization with a clear focus on business and corporate development activities around CureVac’s versatile mRNA technology platform.
- Established in 2015, CureVac Inc. provides a US base of operations for CureVac AG to capitalize on its research and business initiatives as the company advances its pipeline of mRNA therapeutics targeting oncology and infectious diseases, as well as molecular therapies designed to trigger the body's own production of therapeutic proteins. In this regard, Mr. Menichella and his team will be responsible for maximizing the value of these technologies by enabling CureVac to more directly engage pharmaceutical communities, particularly those in the US.
- Mr. Menichella has held a variety of corporate and business development roles for a number of leading companies during his career, including Bamboo Therapeutics, Applied Genetic Technologies Corp., Zyngenia Inc., Talecris Biotherapeutics Holdings Corp. and Merck KGaA. In these roles, Mr. Menichella led major M&A and licensing deals, corporate strategy and commercialization activities.
Financial terms:
Latest news:
Is general: Yes
